BUTI, Sebastiano

BUTI, Sebastiano  

Dipartimento di Medicina e Chirurgia  

Mostra records
Risultati 1 - 20 di 331 (tempo di esecuzione: 0.222 secondi).
Titolo Data di pubblicazione Autore(i) File
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 1-gen-2021 Mazzaschi, G.; Scandino, R.; Milanese, G.; Pavone, C.; Maurizio, B.; Silva, M.; Ledda, R.; Minari, R.; Trentini, F.; Buti, S.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Romanel, A.; Tiseo, M.
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) 1-gen-2022 Stellato, M.; Buti, S.; Maruzzo, M.; Bersanelli, M.; Ermacora, P.; Maiorano, B. A.; Prati, V.; De Giorgi, U. F. F.; Pierantoni, F.; Malgeri, A.; Mennitto, A.; Cavo, A.; Vitale, M. G.; Santoni, M.; Carella, C.; Procopio, G.; Verzoni, E.; Santini, D.
1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study 1-gen-2022 Rebuzzi, S. E.; Rescigno, P.; Signori, A.; Brunelli, M.; Galuppini, F.; Vellone, V. G.; Gaggero, G.; Maruzzo, M.; Milella, M.; Vignani, F.; Cavo, A.; Basso, U.; Catalano, F.; Murianni, V.; Cremante, M.; Damassi, A.; Llaja Obispo, M. A.; Banna, G. L.; Buti, S.; Fornarini, G.
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 1-gen-2021 Mazzaschi, G.; Milanese, G.; Moron Dalla Tor, L.; Leo, L.; Balbi, M.; Trentini, F.; Manini, M.; Pavone, C.; Silva, M.; Ledda, R. E.; Minari, R.; Bordi, P.; Buti, S.; Leonetti, A.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
7 Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon α-2° as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial 1-gen-2007 Chiesa, Md; Passalacqua, R; Michiara, M; Franciosi, V; Di Costanzo, F; Bisagni, G; Camisa, R; Buti, S; Tomasello, G; Cocconi, G; Italian Oncology Group for Clinical, Research.
A new modified sunitinib schedule for metastatic renal cell cancer (mRCC): A pilot study 1-gen-2012 Buti, S; Donini, M; Lazzarelli, S; Brighenti, M; Passalacqua, R
Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib 1-gen-2020 Cerbone, L.; Rebuzzi, S. E.; Lattanzi, E.; Gnetti, L.; Iaia, M. L.; D'Abbiero, N.; Buti, S.
Activating c-kit mutations in a subset of thymic carcinoma and response to different c-kit inhibitors 1-gen-2012 Schirosi, L.; Nannini, N.; Nicoli, D.; Cavazza, A.; Valli, R.; Buti, S.; Garagnani, L.; Sartori, G.; Calabrese, F.; Marchetti, A.; Buttitta, F.; Felicioni, L.; Migaldi, M.; Rea, F.; Di chiara, F.; Mengoli, M. C.; Rossi, G.
Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report 1-gen-2020 Zielli, T.; Gnetti, L.; Buti, S.
Adjuvant low-dose IL2 plus IFNα in operable renal cell carcinoma: a phase III, randomized, multicenter trial 1-gen-2008 Vaglio, A; Alberici, F; Buti, S; Porta, C; Dal Canton, A; Potenzoni, D; Passalacqua, R; Caminiti, C; Buzio, C
Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-a (IFN-a) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC) (vol 37, pg 440, 2014) 1-gen-2014 Passalacqua, R; Caminiti, C; Buti, S
Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-alpha (IFN-alpha) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC) 1-gen-2014 Passalacqua, R; Caminiti, C; Buti, S; Porta, C; Camisa, R; Braglia, L; Tomasello, G; Vaglio, A; Labianca, R; Rondini, E; Sabbatini, R; Nastasi, G; Artioli, F; Prati, A; Potenzoni, M; Pezzuolo, D; Oliva, E; Alberici, F; Buzio, C
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): A phase III, randomized, multicentre trial of the italian oncology group for clinical research (GOIRC) 1-gen-2014 Passalacqua, R.; Caminiti, C.; Buti, S.; Porta, C.; Camisa, R.; Braglia, L.; Tomasello, G.; Vaglio, A.; Labianca, R.; Rondini, E.; Sabbatini, R.; Nastasi, G.; Artioli, F.; Prati, A.; Potenzoni, M.; Pezzuolo, D.; Oliva, E.; Alberici, F.; Buzio, C.
Adjuvant low-dose interleukin-2 (IL2) plus interferon-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the italian oncology group for clinical research (GOIRC) 1-gen-2007 Passalacqua, R; Buzio, C; Potenzoni, D; Buti, S; Labianca, R; Porta, C; Nastasi, P; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Alberici, F; Bongiovanni, C; Pezzuolo, D; Caminiti, C
Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC) 1-gen-2007 Passalacqua, R; Buzio, C; Buti, S; Labianca, R; Porta, C; Boni, C; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Caminiti, C
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) 1-gen-2018 Leonetti, A.; Zielli, T.; Buti, S.
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 1-gen-2015 Bozzetti, Cecilia; Nizzoli, Rita; Tiseo, Marcello; Squadrilli, Anna; Lagrasta, Costanza Anna Maria; Buti, Sebastiano; Gasparro, Donatello; Zanoni, Daniele; Majori, Maria; DE FILIPPO, Massimo; Mazzoni, Francesca; Maddau, Cristina; Naldi, Nadia; Sammarelli, Gabriella; Frati, Caterina; Pinto, Carmine; Ardizzoni, Andrea
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 1-gen-2017 Tiseo, Marcello; Damato, Angela; Longo, Lucia; Barbieri, Fausto; Bertolini, Federica; Stefani, Alessandro; Migaldi, Mario; Gnetti, Letizia; Camisa, Roberta; Bordi, Paola; Buti, Sebastiano; Rossi, Giulio
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 1-gen-2020 Cortellini, A.; Bersanelli, M.; Santini, D.; Buti, S.; Tiseo, M.; Cannita, K.; Perrone, F.; Giusti, R.; De Tursi, M.; Zoratto, F.; Marconcini, R.; Russano, M.; Zeppola, T.; Anesi, C.; Filetti, M.; Marchetti, P.; Botticelli, A.; Gelibter, A.; De Galitiis, F.; Vitale, M. G.; Rastelli, F.; Tudini, M.; Silva, R. R.; Atzori, F.; Chiari, R.; Ricciuti, B.; De Giglio, A.; Migliorino, M. R.; Mallardo, D.; Vanella, V.; Mosillo, C.; Bracarda, S.; Rinaldi, S.; Berardi, R.; Natoli, C.; Ficorella, C.; Porzio, G.; Ascierto, P. A.
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? 1-gen-2021 Roviello, G.; Buti, S.; Cattrini, C.; Mennitto, A.; Messina, C.; Airoldi, C.; Vannini, G.; Bersanelli, M.